- Home
- CLVT vs MLTX Comparison
CLVT vs MLTX Comparison
Compare CLVT & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLVT | MLTX |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United Kingdom | Switzerland |
| Employees | 12000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLVT | MLTX |
|---|---|---|
| Price | $1.96 | $17.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $3.22 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 7.3M | 1.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $5.95 |
| 52 Week High | $4.56 | $62.75 |
Technical Indicators
Market Signals| Indicator | CLVT | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 40.28 |
| Support Level | $1.66 | $17.00 |
| Resistance Level | $2.65 | $19.24 |
| Average True Range (ATR) | 0.19 | 0.97 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 28.30 | 0.71 |
Price Performance
Historical ComparisonAbout CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.